Ispecimen Inc. Stock Price, News & Analysis

iSpecimen (NASDAQ: ISPC) has announced plans to establish a $200 million corporate treasury built around Solana cryptocurrency. The biospecimen technology company has partnered with BlockArrow, a digital asset advisory firm, and WestPark Capital to guide this strategic initiative.

The treasury will leverage Solana's blockchain ecosystem, chosen for its high throughput, low transaction costs, and enterprise security features. BlockArrow will implement a layered security model including offline cold storage and insured custody through Coinbase Custody, backed by Lloyd's of London.

This strategic move represents iSpecimen's commitment to integrating digital assets into its business model and positioning itself as a leader in blockchain adoption within the life sciences sector.

iSpecimen (Nasdaq: ISPC), an online marketplace for biospecimens, has completed a $1.75 million private placement of common stock and pre-funded warrants. The company issued 1,559,828 shares at $1.122 per share, priced at-the-market under Nasdaq rules.

Of the net proceeds, $500,000 will be allocated to marketing and advertising services through IR Agency LLC, with the remainder supporting working capital and general corporate purposes. WestPark Capital served as the exclusive placement agent for the offering, which closed on August 4, 2025.

iSpecimen (Nasdaq: ISPC), an online marketplace for biospecimens, has announced a $1.75 million private placement of securities priced at-the-market. The company will issue 1,559,828 shares of common stock (or pre-funded warrants) at $1.122 per share.

The offering, expected to close around August 1, 2025, will be placed through WestPark Capital, Inc. Of the proceeds, $500,000 will be allocated to marketing services through IR Agency LLC, with the remainder used for working capital and general corporate purposes. The securities are being offered exclusively to accredited investors and will require registration with the SEC for resale.

iSpecimen (Nasdaq: ISPC) has successfully closed its previously announced underwritten public offering, raising approximately $4 million through the sale of 5,714,283 shares of common stock at $0.70 per share. The biospecimen marketplace company plans to allocate $1.5 million for marketing services through IR Agency LLC and $1 million for an initial milestone payment to Sales Stack Solutions Corp., with the remainder designated for working capital.

WestPark Capital, Inc. served as the Sole Book-Runner for this firm commitment offering, which was conducted under an effective S-1 registration statement. This press release corrects an earlier version that incorrectly listed KCSA Strategic Communications as iSpecimen's investor relations contact.

iSpecimen (Nasdaq: ISPC), an online marketplace for biospecimens, has announced the pricing of an underwritten public offering of 5,714,283 shares at $0.70 per share, aiming to raise approximately $4 million in gross proceeds.

The company plans to allocate $1.5 million for marketing services through IR Agency LLC, $1 million for an initial milestone payment to Sales Stack Solutions Corp., and the remainder for working capital. WestPark Capital is serving as the Sole Book-Runner, with the offering expected to close on July 25, 2025.

iSpecimen (NASDAQ:ISPC), an online marketplace for biospecimens, has completed its previously announced underwritten public offering, raising $4 million in gross proceeds. The offering consisted of 5,714,283 shares of common stock (or pre-funded warrants) priced at $0.70 per share.

The Company plans to allocate $1.5 million for marketing services through IR Agency LLC, $1 million for an initial milestone payment to Sales Stack Solutions Corp., with the remaining funds designated for working capital and general corporate purposes. WestPark Capital, Inc. served as the Sole Book-Runner for this firm commitment offering.

iSpecimen (Nasdaq: ISPC), an online marketplace for biospecimens, has announced the pricing of a $4 million underwritten public offering. The company is offering 5,714,283 shares of common stock at $0.70 per share, with closing expected on July 25, 2025.

The net proceeds will be allocated as follows: $1.5 million for marketing services through IR Agency LLC, $1 million for an initial milestone payment to Sales Stack Solutions Corp., and the remainder for working capital. WestPark Capital, Inc. is serving as the Sole Book-Runner for this firm commitment offering.

iSpecimen (NASDAQ: ISPC), a leading online biospecimen marketplace, has secured suppliers for human metapneumovirus (hMPV) specimens amid growing concerns over the virus outbreak in China. The flu-like virus, which causes upper respiratory infections, has been overwhelming Chinese hospitals, raising concerns about a potential COVID-style pandemic.

hMPV spreads through respiratory droplets and can be severe in elderly, immunocompromised, and chronically ill patients. Unlike COVID-19, flu, and RSV, there is currently no vaccine available for hMPV. The virus is difficult to differentiate from these other respiratory infections.

Through its global network of suppliers, iSpecimen is positioning itself to meet the anticipated demand for specimens needed for vaccine development and virus research. The company's strategic partnerships with high-value suppliers and streamlined procurement processes aim to ensure reliable access to quality specimens as concerns grow about the virus's spread.

iSpecimen Inc. (NASDAQ: ISPC) has announced strategic initiatives for 2025 focused on expanding its cancer biospecimen procurement services. The company plans to establish new partnerships with U.S.-based cancer centers to increase access to domestic cancer blood products and will collaborate with an international genomic sequencing partner as a preferred provider of cancer biospecimens.

The initiative responds to growing market demand for cancer tissue in medical research. iSpecimen will implement a data-driven approach for documenting supplier capabilities and pricing, offering rapid competitive quotes. The company also plans to expand its portfolio with new remnant biofluid cancer offerings from recently partnered sites, providing cost-effective samples with diagnostic codes for target discovery and validation.